Target Name: USP17L1
NCBI ID: G401447
Review Report on USP17L1 Target / Biomarker Content of Review Report on USP17L1 Target / Biomarker
USP17L1
Other Name(s): Ubiquitin specific peptidase 17-like 1 (pseudogene) | ubiquitin-specific-processing protease 17-like protein 1 | deubiquitinating enzyme 17-like protein 1 | Deubiquitinating enzyme 17-like protein 1 | Ubiquitin-specific-processing protease 17-like protein 1 | Ubiquitin specific peptidase 17 like family member 1 | ubiquitin specific peptidase 17 like family member 1 | Ubiquitin thioesterase 17-like protein 1 | Ubiquitin specific peptidase 17-like 1, pseudogene | Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 | U17L1_HUMAN | USP17L1P | putative ubiquitin carboxyl-terminal hydrolase 17-like protein 1 | ubiquitin thioesterase 17-like protein 1

USP17L1: A Potential Drug Target and Biomarker

USP17L1, also known as Ubiquitin Specific Peptidase 17-Like 1 (pseudogene), is a protein that plays a critical role in the regulation of protein degradation in the body. It is a 21-kDa protein that is expressed in a variety of tissues and cells, including the liver, muscle, and brain. USP17L1 has been identified as a potential drug target and biomarker due to its unique structure and its involvement in the regulation of protein homeostasis.

The protein encoded by the USP17L1 gene is composed of 21 amino acid residues. It has a molecular weight of 21 kDa and a pre-protein N-terminal extension of 14 amino acids. The N-terminal extension includes a unique feature that is not found in any other protein, known as a \"PEG-like\" region. This region consists of a single amino acid residue that is modified with a 4-mercaptoethoxybenzaldehyde (Me-O-Me) group. The Me-O-Me group is a derivative of the amino acid glutamic acid, which is known for its ability to bind to metal ions and to participate in various cellular processes, including the regulation of protein stability and degradation.

The unique structure of USP17L1 has led to its potential as a drug target. One of the key features of USP17L1 is its ability to interact with a variety of protein substrates, including other Ubiquitin proteins. USP17L1 has been shown to interact with several Ubiquitin proteins, including Ubiquitin alpha (UBA), Ubiquitin beta (UBB), and Ubiquitin delta (UBD). These interactions are important for the regulation of protein stability and degradation, and may be targeted by drugs that target the activity of USP17L1.

In addition to its potential as a drug target, USP17L1 also has the potential as a biomarker. The regulation of protein homeostasis is a critical process that is involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Alterations in the regulation of protein homeostasis have been implicated in the development and progression of these diseases, and may be targeted by drugs that target USP17L1.

The USP17L1 protein has been shown to play a critical role in the regulation of protein homeostasis in a variety of tissues and cells. For example, studies have shown that USP17L1 is involved in the regulation of protein stability and degradation in the liver, muscle, and brain. Additionally, USP17L1 has been shown to interact with several Ubiquitin proteins, including Ubiquitin alpha, Ubiquitin beta, and Ubiquitin delta. These interactions may be targeted by drugs that target the activity of USP17L1, making it a potential drug target and biomarker.

Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 1

Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection

The "USP17L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT